Self-Reported Symptoms of Empagliflozin Discontinuation – An Online Survey
Abstract
ABSTRACT
Background and Aim: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent a new class of antidiabetic medications that offer benefits such as weight reduction and a decreased risk of cardiovascular diseases. Nevertheless, the use of SGLT2i is associated with a range of potential side effects.The present study aimed to analyze the rate of discontinuation for empagliflozin and investigated the incidence of its side effects.
Patients and Methods: This study employed a cross-sectional design using an online survey to collect data of 567 patients on pots-withdrawal symptoms of empagliflozin. Adults (≥ 18 years) who had taken empagliflozin for at least three months and had discontinued for any reasons included. Participants recruited through online platforms, including social media and online forum. The survey collected demographic information, empagliflozin use and discontinuation, reasons for discontinuation, and post-withdrawal symptoms. SPSS version 26 used for statistical analysis.
Results: Out of 567 patients, majority of patients prescribed Jardiance for diabetes 75% (n=425) and heart failure 25% (n=142). Genital infections 27% (n=109) and UTIs 22% (n=90)were the leading reasons for discontinuation followed by Dry mouth/frequent urination 17% (n=70), Lack of efficacy 14% (n=55), low blood pressure 11% (n=45), and Ketoacidosis 9% (n=35). About 67% (n=231) cases withdrawal was perceived due to adversely affect. Headache 20% (n=60) and swelling 17% (n=50) were…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.